{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:34:21Z","timestamp":1793468061052,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.atherosclerosis.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T23:04:40Z","timestamp":1447110280000},"page":"44-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies"],"prefix":"10.1016","volume":"244","author":[{"given":"Gerd","family":"Wallukat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-3117","authenticated-orcid":false,"given":"Johannes","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathrin","family":"Haberland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst-Joachim","family":"Freyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Salzsieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Schimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00281-014-0425-9","article-title":"Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases","volume":"36","author":"Wallukat","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib2","first-page":"S634","article-title":"Effects of gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes","volume":"46","author":"Wallukat","year":"1987","journal-title":"Biomed. Biochim. Acta"},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0167-5273(96)02589-2","article-title":"Anti-M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy","volume":"54","author":"Fu","year":"1996","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2009.06.064","article-title":"Distinct pattern of autoantibodies against G-protein coupled receptors in Chagas' cardiomyopathy and megacolon","volume":"55","author":"Wallukat","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2015.11.001_bib5","doi-asserted-by":"crossref","first-page":"e86770","DOI":"10.1371\/journal.pone.0086770","article-title":"The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-3083.2009.02280.x","article-title":"Sera of patients with type2 diabetes contain agonistic autoantibodies against G-protein coupled receptors","volume":"70","author":"Hempel","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.HYP.29.2.678","article-title":"Alpha1-adrenergic receptor antibodies in patients with primary hypertension","volume":"29","author":"Luther","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib8","first-page":"S1072","article-title":"Potential pathogenetic involvement of agonistic autoantibodies against alpha-1 adrenergic and endothelin-1 receptors in pulmonary arterial hypertension","volume":"118","author":"Dandel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/eurjhf\/hfs123","article-title":"Long-term benefits of immunoadsorption in \u03b2(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy","volume":"14","author":"Dandel","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosissup.2015.02.023","article-title":"Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus","volume":"18","author":"Dandel","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tcm.2012.05.006","article-title":"Aptamer binding and neutralization of \u03b21-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment","volume":"21","author":"Haberland","year":"2011","journal-title":"Trends Cardiovasc Med."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-014-2057-8","article-title":"Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in\u00a0vivo: the first successful proof of principle in spontaneously hypertensive rats","volume":"393","author":"Haberland","year":"2014","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Ellington","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib14","first-page":"258","article-title":"Toxicological evaluation of oligonucleotide therapeutics","volume":"2","author":"Marquis","year":"2000","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib15","unstructured":"Schimke I, Haberland A, Wallukat G. Use of aptamers in therapy and\/or diagnosis of autoimmune diseases. EP 2012\/2497828A1, WO 2012\/2012119938A2."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCRESAHA.111.253849","article-title":"Aptamer neutralization of beta1-adrenoceptror autoantibodies isolated from patients with cardiomyopathies","volume":"109","author":"Haberland","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib17","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1056\/NEJM200211283472220","article-title":"Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy","volume":"347","author":"Wallukat","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2015.11.001_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jca.20050","article-title":"Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study","volume":"20","author":"Schimke","year":"2005","journal-title":"J.\u00a0Clin. Apher."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib19","unstructured":"Jahns R, Jahns V, Lohse M, Palm D. Means for the inhibition of anti-1-adrenergic receptor antibodies. WO 2006\/103101 A2."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.atherosclerosissup.2012.10.029","article-title":"Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension","volume":"14","author":"Dandel","year":"2013","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2015.11.001_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-3083.2012.02684.x","article-title":"Agonistic autoantibodies to the \u03b11-adrenergic and the \u03b22-adrenergic receptor in Alzheimer's and vascular dementia","volume":"75","author":"Karczewski","year":"2012","journal-title":"Scand. J. Immunol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2015.11.001_bib22","doi-asserted-by":"crossref","first-page":"e41602","DOI":"10.1371\/journal.pone.0041602","article-title":"Antibodies to the \u03b11-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography","volume":"7","author":"Karczewski","year":"2012","journal-title":"PLoS One"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015301970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015301970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T18:50:27Z","timestamp":1537210227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015301970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":22,"alternative-id":["S0021915015301970"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.11.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}